Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN L A versus DURACILLIN A S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN L A versus DURACILLIN A S.
BICILLIN L-A vs DURACILLIN A.S.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine is a slow-release formulation that provides prolonged tissue concentrations. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes, leading to cell lysis.
Penicillin G procaine is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1.2 million units intramuscularly as a single dose for treatment of streptococcal pharyngitis; for syphilis, 2.4 million units intramuscularly weekly for 1-3 weeks depending on stage.
600,000 units intramuscularly once daily; or 1.2 million units intramuscularly every 12 hours for severe infections.
None Documented
None Documented
Terminal half-life: 30-60 hours (prolonged due to slow absorption from IM depot; clinically allows single-dose regimen for syphilis)
0.5-1 hour in adults with normal renal function; prolonged to 7-10 hours in end-stage renal disease
Renal: 60-90% unchanged; biliary/fecal: minor (<10%)
Primarily renal (60-90% unchanged via tubular secretion and glomerular filtration); minor biliary/fecal elimination (<10%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic